New Blood Tests for TB Could Accelerate Diagnosis
By LabMedica International staff writers Posted on 30 Jan 2019 |
Image: The ELISpot TB diagnostic test kit for tuberculosis (Photo courtesy of Oxford Immunotec).
Tuberculosis (TB) is a bacterial infection affecting the lungs, causing cough, weight loss and fevers, and is spread through droplets from coughs and sneezes from infected patients. Diagnosing and treating the condition early is essential for the health of the patient as well as for preventing the spread of TB to others.
There is therefore a need for rapid, convenient tests to rule out a TB diagnosis in suspected cases based on a blood sample. While laboratory cultures of patient samples, such as sputum or invasive biopsies, are used to confirm the presence of the bacterium, the cultures can take several weeks. A negative result does not rule out a diagnosis of TB, as the bacteria cannot be cultured from samples in a large proportion of TB patients.
A team of British scientists working with the Imperial College London (London, UK) carried out a prospective study comparing existing commercially available interferon-gamma release-assays (IGRA) against new generation tests in 845 patients with suspected TB in 10 NHS hospitals in England. Patient blood samples were analyzed using both sets of tests, the results of which benchmarked against a confirmed diagnoses based on positive culture results.
Patients were tested for Mycobacterium tuberculosis infection at baseline with commercially available assays: T-SPOT. TB and QuantiFERON-TB Gold In-Tube and second-generation IGRAs incorporating novel M tuberculosis antigens, and followed up for six to12 months to establish definitive diagnoses. These new antigens are used in the generic ELISpot (enzyme-linked immunospot) platform technology on which the commercial T-SPOT.TB test is based. Sensitivity, specificity, positive and negative likelihood ratios, and predictive values of the tests were determined.
Analysis of the rapid test results revealed that the second-generation test has a diagnostic sensitivity of 94% in patients with confirmed TB - meaning it gives a positive result for 94% of patients with infection, significantly and substantially higher than either of the existing commercially available IGRA tests, which range from 67.3% and 81.4%. The findings indicate the test would be much more accurate at ruling out TB infection in suspected cases of TB, so saving time and resources and enabling patients to receive treatment more rapidly.
The authors concluded that commercially available IGRAs do not have sufficient accuracy for diagnostic evaluation of suspected tuberculosis. Second-generation tests, however, might have sufficiently high sensitivity, low negative likelihood ratio, and correspondingly high negative predictive value in low-incidence settings to facilitate prompt rule-out of tuberculosis.
Ajit Lalvani, DM, a professor of Infectious Diseases and a co-author of the study, said, “Tens of thousands of patients undergo diagnostic assessment for symptoms suggestive of TB, resulting in over 5,000 cases of TB diagnosed each year. Stopping the use of the existing, inadequate tests could save the NHS a lot of money. In contrast, the new, more accurate rapid blood test will improve and accelerate diagnostic assessment of patients with suspected TB.” The study was published on January 14, 2019, in the journal Lancet Infectious Diseases.
There is therefore a need for rapid, convenient tests to rule out a TB diagnosis in suspected cases based on a blood sample. While laboratory cultures of patient samples, such as sputum or invasive biopsies, are used to confirm the presence of the bacterium, the cultures can take several weeks. A negative result does not rule out a diagnosis of TB, as the bacteria cannot be cultured from samples in a large proportion of TB patients.
A team of British scientists working with the Imperial College London (London, UK) carried out a prospective study comparing existing commercially available interferon-gamma release-assays (IGRA) against new generation tests in 845 patients with suspected TB in 10 NHS hospitals in England. Patient blood samples were analyzed using both sets of tests, the results of which benchmarked against a confirmed diagnoses based on positive culture results.
Patients were tested for Mycobacterium tuberculosis infection at baseline with commercially available assays: T-SPOT. TB and QuantiFERON-TB Gold In-Tube and second-generation IGRAs incorporating novel M tuberculosis antigens, and followed up for six to12 months to establish definitive diagnoses. These new antigens are used in the generic ELISpot (enzyme-linked immunospot) platform technology on which the commercial T-SPOT.TB test is based. Sensitivity, specificity, positive and negative likelihood ratios, and predictive values of the tests were determined.
Analysis of the rapid test results revealed that the second-generation test has a diagnostic sensitivity of 94% in patients with confirmed TB - meaning it gives a positive result for 94% of patients with infection, significantly and substantially higher than either of the existing commercially available IGRA tests, which range from 67.3% and 81.4%. The findings indicate the test would be much more accurate at ruling out TB infection in suspected cases of TB, so saving time and resources and enabling patients to receive treatment more rapidly.
The authors concluded that commercially available IGRAs do not have sufficient accuracy for diagnostic evaluation of suspected tuberculosis. Second-generation tests, however, might have sufficiently high sensitivity, low negative likelihood ratio, and correspondingly high negative predictive value in low-incidence settings to facilitate prompt rule-out of tuberculosis.
Ajit Lalvani, DM, a professor of Infectious Diseases and a co-author of the study, said, “Tens of thousands of patients undergo diagnostic assessment for symptoms suggestive of TB, resulting in over 5,000 cases of TB diagnosed each year. Stopping the use of the existing, inadequate tests could save the NHS a lot of money. In contrast, the new, more accurate rapid blood test will improve and accelerate diagnostic assessment of patients with suspected TB.” The study was published on January 14, 2019, in the journal Lancet Infectious Diseases.
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form